Dedifferentiated liposarcoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A high-grade subtype of liposarcoma (LS) that progresses from well-differentiated liposarcoma (WDLS), and most often occurs in the retroperitoneum. It is defined as a region of nonlipogenic sarcoma associated with WDLS.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Dedifferentiated liposarcoma
- Therapeutic area
- Oncology
- dedifferentiated liposarcoma
- DDLPS
- DDLS
- dedifferentiated liposarcoma
- Severity
- Severe
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0020563
- Parent condition
- MONDO:0005060
Related records
Broader conditions (19)
- Cancer
- Cancer or benign tumor
- Connective and soft tissue neoplasm
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Lipomatous cancer
- Liposarcoma
- Malignant soft tissue neoplasm
- Mesenchymal cell neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Sarcoma
- Soft tissue neoplasm
- Soft tissue sarcoma
- Tumor of adipose tissue
Trials (36)
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
- A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
- A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
- Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
- Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
- Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
- Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
- First-line Treatment of Advanced/unresectable DDLPS
- Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
- Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
- Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
- Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
- Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
Approved drugs (1)
- Trabectedin
Drugs in development (17)
- Abemaciclib Phase 3
- Brigimadlin Phase 3
- Cabazitaxel Phase 2
- Cemiplimab Phase 2
- Doxorubicin Phase 2
- Ipilimumab Phase 2
- Milademetan Phase 3
- Nivolumab Phase 2
- Palbociclib Phase 2
- Pemigatinib Phase 2
- Pioglitazone Phase 2
- Plitidepsin Phase 2
- Retaspimycin hydrochloride Phase 2
- Retifanlimab Phase 2
- Ribociclib Phase 2
- Selinexor Phase 2
- TP-1287 Phase 1